IPSS Score Proves Its Clinical Relevance in Benign Prostate Hypertrophy Diagnosis and Follow-Up

Key-words: 5-alphareductase inhibitors, alpha-blocker treatment, BPH, IPSS, LUTS, phytotherapy Introduction and Objectives The benign hypertrophy of prostate (BPH) is the histopathological diagnosis of prostate adenoma, which is a benign tumor of the prostate characterized by the proliferation of pr...

Full description

Saved in:
Bibliographic Details
Published inRomanian journal of urology Vol. 17; no. 3; pp. 16 - 22
Main Authors Miklos, I, Mureşanu, H D, Greluş, A I, Ioiart, I
Format Journal Article
LanguageEnglish
Published Bucharest Romanian Journal of Urology 01.07.2018
Subjects
Age groups
Ethnicity
Hyperplasia
Population
Prostate cancer
Quality of life
Questionnaires
Studies
Ultrasonic imaging
Urogenital system
Urology
Romania
Online AccessGet full text

Cover

More Information
Summary:Key-words: 5-alphareductase inhibitors, alpha-blocker treatment, BPH, IPSS, LUTS, phytotherapy Introduction and Objectives The benign hypertrophy of prostate (BPH) is the histopathological diagnosis of prostate adenoma, which is a benign tumor of the prostate characterized by the proliferation of prostatic stromal and epithelial cells and by the appearance of LUTS (lower urinary tract symptoms). Complications of the BPH occur less commonly but may include acute urinary retention (AUR), impaired bladder emptying, the need for corrective surgery, renal failure, recurrent urinary tract infections, bladder stones, or gross hematuria [4,5]. According to the EAU Guideline 2017 for the management of LUTS, a validated symptome score questionnaire should be used for the routine assessment of male LUTS in all patients and same should be applied for re-evaluation of LUTS during treatment. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
ISSN:1842-2187